New Thalidomide Analogs for Retinal Neovacularization

Award Information
Agency: Department of Health and Human Services
Branch: N/A
Contract: 1R43EY016627-01
Agency Tracking Number: EY016627
Amount: $149,800.00
Phase: Phase I
Program: SBIR
Awards Year: 2005
Solicitation Year: 2005
Solicitation Topic Code: N/A
Solicitation Number: PHS2005-2
Small Business Information
Charlesson, Llp, 7005 Trenton Rd, Oklahoma City, OK, 73116
HUBZone Owned: N
Woman Owned: Y
Socially and Economically Disadvantaged: N
Principal Investigator
 (405) 271-4629
Business Contact
Phone: (405) 413-6290
Research Institution
DESCRIPTION (provided by applicant): Diabetic retinopathy is a common complication of diabetes mellitus and a leading cause of blindness in the developed countries. There are two major pathological changes which impair vision in diabetic retinopathy: diabetic macular edema (DME) resulting from increased retinal vascular permeability and abnormal angiogenesis in the retina or retinal neovascularization (NV). Currently, there is no effective drug treatment for DME and retinal NV. Over-expression of vascular endothelial growth factor (VEGF) is believed to play a critical role in the development of DME and retinal NV. Thalidomide and its analogs have been shown to have anti-angiogenic activities and have been used for the treatments of multiple myenoma and several cancers. The application of thalidomide and its existing analogs in the treatment of retinal neovascular disorders is limited due to their weak anti-angiogenic activities. Novel compounds with improved anti-angiogenic activities are needed. Recently, our collaborator has synthesized a series of novel thalidomide analogs by substituting the glutaramide ring of thalidomide with an aromatic group. The in vitro assays have shown that three of these analogs have more potent anti-agiogenic activity than thalidomide and other existing analogs. We hypothesize that these analogs have therapeutic potential in the treatment of DME and retinal NV. This Phase I project will serve as a proof-of-concept study to confirm the anti-angiogenic effect of the three thalidomide analogs on retinal NV in a rat model of oxygen-induced retinopathy (OIR), a commonly used animal model of retinal NV. We will determine if these compounds can prevent the development of retinal NV and arrest its progression. As these compounds block the expression of HIF-1, a key transcription factor up-regulating VEGF expression, we hypothesize that they may also reduce vascular permeability in diabetic retina. The effect of these compounds on retinal vascular permeability will be determined in steptozotocin-induced diabetic rats. The effect of these compounds will be compared with that of thalidomide. These studies will not only reveal the therapeutic potenital of these compounds in the treatment of retinal NV and DME, but also determine if they are more potent than thalidomide. The Phase I project will lay a solid ground for the Phase II to investigate the mechanism, delivery routes, metabolism and toxicities of these compounds. Therefore, this project has potential to develop novel anti-angiogenic drugs with improved potency.

* Information listed above is at the time of submission. *

Agency Micro-sites

SBA logo
Department of Agriculture logo
Department of Commerce logo
Department of Defense logo
Department of Education logo
Department of Energy logo
Department of Health and Human Services logo
Department of Homeland Security logo
Department of Transportation logo
Environmental Protection Agency logo
National Aeronautics and Space Administration logo
National Science Foundation logo
US Flag An Official Website of the United States Government